Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Liver Diseases

Free Subscription 24.10.2022 1 Am J Pathol 2 BMC Cancer 1 BMC Gastroenterol 4 Br J Surg 1 Cancer Res 1 Dig Dis 1 Dig Dis Sci 1 Gastroenterology 2 Gastrointest Endosc 13 Hepatology 2 J Gastroenterol Hepatol 14 J Hepatol 1 Oncogene 3 PLoS One 1 Radiology 1 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. ARGEMI J, Kedia K, Gritsenko MA, Clemente-Sanchez A, et al
   Integrated Transcriptomic and Proteomic Analysis Identifies Plasma Biomarkers of Hepatocellular Failure in Alcohol-Associated Hepatitis.
   Am J Pathol. 2022 Oct 13. pii: S0002-9440(22)00310.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. ZHU W, Shi P, Liang A, Zhu Y, et al
   The combination of serum oligosaccharide chain (G-test), alpha-fetoprotein, and aspartate aminotransferase to alanine aminotransferase ratio provides the optimal diagnostic value for early detection of hepatocellular carcinoma.
   BMC Cancer. 2022;22:1061.
   PubMed         Abstract available
   
   
3. YANG TK, Yu YF, Tsai CL, Li HJ, et al
   Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
   BMC Cancer. 2022;22:1085.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

4. WU R, Liu K, Shi C, Tian H, et al
   Risk factors for portal hypertensive gastropathy.
   BMC Gastroenterol. 2022;22:436.
   PubMed         Abstract available
   
   

   
   Br J Surg

5. D'SILVA M, Han HS, Liu R, Kingham TP, et al
   Limited liver resections in the posterosuperior segments: international multicentre propensity score-matched and coarsened exact-matched analysis comparing the laparoscopic and robotic approaches.
   Br J Surg. 2022;109:1140-1149.
   PubMed         Abstract available
   
   
6. BUETTNER S, Olthof PB, Wang J, Kreis ME, et al
   Author response to: Comment on: KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations.
   Br J Surg. 2022;109:e122.
   PubMed        
   
   
7. LIU QL, Chen HN
   Comment on: KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations.
   Br J Surg. 2022;109:e121.
   PubMed        
   
   
8. SIJBERDEN JP, Abu Hilal M
   Comment on: Synchronous resection of primary colorectal cancer with liver metastases: two birds with one stone?
   Br J Surg. 2022 Jul 16. pii: 6645296. doi: 10.1093.
   PubMed        
   
   

   
   Cancer Res

9. DUDA DG, Jain RK
   Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.
   Cancer Res. 2022;82:3665-3667.
   PubMed         Abstract available
   
   

   
   Dig Dis

10. HONG C, Dong HZ, Li RN, Zhu HB, et al
    Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors.
    Dig Dis. 2022 Oct 18. pii: 000527574. doi: 10.1159/000527574.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

11. LIU YC, Cheng YT, Chen YC, Hsieh YC, et al
    Correction: Comparing Predictability of Noninvasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients.
    Dig Dis Sci. 2022 Oct 17. pii: 10.1007/s10620-022-07683.
    PubMed        
    
    

    
    Gastroenterology

12. RAHAL HK, Tabibian JH, Issaka RB, Quezada S, et al
    Diversity, Equity, and Inclusion in Gastroenterology and Hepatology: A Survey of Where We Stand.
    Gastroenterology. 2022 Oct 7. pii: S0016-5085(22)00721.
    PubMed         Abstract available
    
    

    
    Gastrointest Endosc

13. HUANG Y, Li J, Zheng T, Ji D, et al
    Development and validation of a machine learning-based model for varices screening in compensated cirrhosis (CHESS2001): An international multicenter study.
    Gastrointest Endosc. 2022 Oct 14. pii: S0016-5107(22)02054.
    PubMed         Abstract available
    
    
14. RAHAL HK, Tabibian JH, Issaka RB, Quezada S, et al
    Diversity, equity, and inclusion in gastroenterology and hepatology: a survey of where we stand.
    Gastrointest Endosc. 2022 Oct 5. pii: S0016-5107(22)01938.
    PubMed         Abstract available
    
    

    
    Hepatology

15. TOMLINSON JL, Penrice DD, Ramkissoon R, Udompap P, et al
    Hepatology highlights.
    Hepatology. 2022;76:1231-1232.
    PubMed        
    
    
16. LEI L, Bruneau A, El Mourabit H, Guegan J, et al
    Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis.
    Hepatology. 2022;76:1360-1375.
    PubMed         Abstract available
    
    
17. ZHANG X, Wong GL, Yip TC, Cheung JTK, et al
    Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
    Hepatology. 2022;76:1409-1422.
    PubMed         Abstract available
    
    
18. DENG R, Liu S, Shen S, Guo H, et al
    Circulating hepatitis B virus RNA: From biology to clinical applications.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
    PubMed         Abstract available
    
    
19. VILAR-GOMEZ E, Pirola CJ, Sookoian S, Wilson LA, et al
    PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features.
    Hepatology. 2022;76:1482-1494.
    PubMed         Abstract available
    
    
20. RIMOLA J, Sapena V, Brancatelli G, Darnell A, et al
    Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria.
    Hepatology. 2022;76:1318-1328.
    PubMed         Abstract available
    
    
21. YOUNOSSI ZM, Paik JM, Al Shabeeb R, Golabi P, et al
    Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
    Hepatology. 2022;76:1423-1437.
    PubMed         Abstract available
    
    
22. OLIVEIRA CP
    Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?
    Hepatology. 2022;76:1246-1247.
    PubMed        
    
    
23. SHANG Y, Nasr P, Widman L, Hagstrom H, et al
    Risk of cardiovascular disease and loss in life expectancy in NAFLD.
    Hepatology. 2022;76:1495-1505.
    PubMed         Abstract available
    
    
24. AMADOU C, Nabi O, Serfaty L, Lacombe K, et al
    Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort.
    Hepatology. 2022;76:1438-1451.
    PubMed         Abstract available
    
    
25. VAN KLEEF LA, de Knegt RJ
    The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach?
    Hepatology. 2022;76:1243-1245.
    PubMed        
    
    
26. ATTIA D, Gomaa A, Abdel Alem S
    Letter to the editor: Pitfalls in the outcome differences between NAFLD and MAFLD.
    Hepatology. 2022;76:E100.
    PubMed        
    
    
27. CHUNG HH
    Letter to the editor: The perspective of GLP-1/GLP-2 receptors against NASH via diverse regulation.
    Hepatology. 2022;76:E106-E107.
    PubMed        
    
    

    
    J Gastroenterol Hepatol

28. MEENA BL, Taneja S, Tandon P, Sahni N, et al
    Home-based Intensive Nutrition Therapy improves Frailty and Sarcopenia in Patients with Decompensated Cirrhosis: A Randomized Clinical Trial.
    J Gastroenterol Hepatol. 2022 Oct 21. doi: 10.1111/jgh.16035.
    PubMed         Abstract available
    
    
29. LIU Y, Chen M
    Targeting hepatic stellate cells may serve as a promising target for hepatic steatosis.
    J Gastroenterol Hepatol. 2022 Oct 18. doi: 10.1111/jgh.16028.
    PubMed        
    
    

    
    J Hepatol

30. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    PubMed        
    
    
31. CHEN L, Fan Z, Lv G
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;77:1453-1454.
    PubMed        
    
    
32. DIAO YK, Kong QY, Yang T
    HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?
    J Hepatol. 2022;77:1468-1469.
    PubMed        
    
    
33. HENDRIKX T, Porsch F, Kiss MG, Rajcic D, et al
    Soluble TREM2 levels reflect the recruitment and expansion of TREM2(+) macrophages that localize to fibrotic areas and limit NASH.
    J Hepatol. 2022;77:1373-1385.
    PubMed         Abstract available
    
    
34. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    PubMed         Abstract available
    
    
35. NAOUMOV NV, Brees D, Loeffler J, Chng E, et al
    Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.
    J Hepatol. 2022;77:1399-1409.
    PubMed         Abstract available
    
    
36. TSAI WC, Yu ML, Dai CY
    Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues.
    J Hepatol. 2022;77:1466-1467.
    PubMed        
    
    
37. JIN B, Du S, Yang H
    HBsAg seroclearance reduces the risk of late recurrence in HBV-related HCC.
    J Hepatol. 2022;77:1469-1470.
    PubMed        
    
    
38. TRIPATHI M, Singh BK, Zhou J, Tikno K, et al
    Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.
    J Hepatol. 2022;77:1246-1255.
    PubMed         Abstract available
    
    
39. ALLEN AM, Therneau TM, Ahmed OT, Gidener T, et al
    Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
    J Hepatol. 2022;77:1237-1245.
    PubMed         Abstract available
    
    
40. ENGELMANN C, Habtesion A, Hassan M, Kerbert AJ, et al
    Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.
    J Hepatol. 2022;77:1325-1338.
    PubMed         Abstract available
    
    
41. BOWLUS CL, Levy C, Hirschfield GM
    Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
    PubMed        
    
    
42. PETERMANN-ROCHA F, Ho FK, Pell JP
    Reply to: "Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants".
    J Hepatol. 2022;77:1454-1455.
    PubMed        
    
    
43. VAN KLEEF LA, Kavousi M, de Knegt RJ
    Reply to: "Liver stiffness, fatty liver disease and atrial fibrillation in the Rotterdam study: Some issues".
    J Hepatol. 2022;77:1467-1468.
    PubMed        
    
    

    
    Oncogene

44. WANG X, Liu Y, Han A, Tang C, et al
    The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability.
    Oncogene. 2022 Oct 17. pii: 10.1038/s41388-022-02477.
    PubMed         Abstract available
    
    

    
    PLoS One

45. HAGEMANN CA, Legart C, Mollerhoj MB, Madsen MR, et al
    A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity.
    PLoS One. 2022;17:e0275901.
    PubMed         Abstract available
    
    
46. WU L, Zhuang J, Chen W, Tang Y, et al
    Data augmentation based on multiple oversampling fusion for medical image segmentation.
    PLoS One. 2022;17:e0274522.
    PubMed         Abstract available
    
    
47. LE BOUTILLIER C, Ahmed H, Patel VC, McPhail M, et al
    General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial.
    PLoS One. 2022;17:e0275668.
    PubMed         Abstract available
    
    

    
    Radiology

48. WEIJERS G, Munsterman ID, Thijssen JM, Kuppeveld H, et al
    Noninvasive Staging of Hepatic Steatosis Using Calibrated 2D US with Liver Biopsy as the Reference Standard.
    Radiology. 2022 Oct 18:220104. doi: 10.1148/radiol.220104.
    PubMed         Abstract available
    
    

    
    Transplant Proc

49. KIM JD, Choi DL
    Technical Refinement to Prevent Hepatic Outflow Disturbance in Right Lobe Living Donor Liver Transplantation: The New Simplified One-Orifice Venoplasty Technique.
    Transplant Proc. 2022 Oct 14. pii: S0041-1345(22)00571.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: